Welcome to Molecular Oncology Tumor Boards

The Molecular Oncology Tumor Boards are a series of bi-monthly, user-driven discussions designed to help cancer care providers with the interpretation and understanding of tumor molecular profiling tests and studies. Moderated by an expert pathologist and medical oncologist, each case will be updated with new information over a 2-week period as user comments are added. Sign in with your ASCO username and password to participate. After 2 weeks, the discussion will be locked to further commentary and users will be able to claim CME credit for their participation. Visit ASCO University to learn more. 

To participate in discussions on other oncology-related topics, visit ASCO’s member community on myConnection. Connect with colleagues, build your professional network, exchange ideas, collaborate, and more

LOGIN TO START A DISCUSSION
Molecular Oncology Tumor Board
ASCO University
Feb 10, 2016 9:49 AM
Read more to answer the following questions: 1) Choice for site of biopsy? LN vs. Bone and merits/pros/cons for tissue for molecular profiling vs. confirmation of distant recurrence? 2) Would you recommend clinical genetics consultation for BRCA testing?  Expanded panel testing? 3) What additional...
Molecular Oncology Tumor Board
ASCO University
Jan 13, 2016 9:19 AM
Read more to answer the following questions: 1) What are the pathologic features that distinguish PEComa from the much more common leiomyosarcoma? 2) What is the role for cytotoxic chemotherapy in the treatment of metastatic or unresectable PEComa? 3) Are there any particular genetic targets...
Molecular Oncology Tumor Board
ASCO University
Dec 02, 2015 10:12 AM
Read more to answer the following questions: 1) Who should get routine molecular testing at diagnosis for NSCLC and what tests should be performed? 2)  Given this patient’s age and smoking history are you surprised at the finding of an EGFR mutation? 3) What is the most appropriate initial...
Molecular Oncology Tumor Board
ASCO University
Nov 04, 2015 10:35 AM
Read more to answer the following questions: 1) Does this tumor have a variant morphology and is it significant clinically? 2.) What are the diagnostic/staging studies at this point? 3.) What are treatment options for this patient? 4.) Which tumor gene mutational analysis, if any, might aid in...
Molecular Oncology Tumor Board
ASCO University
Oct 14, 2015 10:22 AM
Read more to answer the following questions: 1. In general, would you be more inclined to offer a targeted therapy regimen or an immune therapy regimen? 2. If a BRAF-targeted therapy approach is selected, what therapeutic options are the most appropriate? 3. If an immune-targeted therapy approach...

Pages


Advertisement